RNAi

Type: Keyphrase
Name: RNAi
First reported 13 hours ago - Updated 13 hours ago - 1 reports

The Biotech Bull Market Is Far From Over

NASDAQ:GILD, NYSEMKT:INO, NASDAQ:ARIA Related posts: The biotech bull market is not over. That’s the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares ... [Published Chicago Daily Herald - 13 hours ago]
First reported 17 hours ago - Updated 17 hours ago - 1 reports

Tekmira Receives Notice of Clinical Hold for TKM-Ebola Phase I Clinical Trial

(GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has received verbal notice from the U. S. Food and Drug Administration (FDA) ... [Published Drugs.com - 17 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Arrowhead Issues a Statement on Intellectual Property Protection for ARC-52008-07-2014

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today reaffirmed its belief that it has broad access to intellectual property required to develop ARC-520, its clinical candidate against ... [Published Pharma Letter - 20 hours ago]
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Global RNAi Technologies, Markets and Companies (Updated 2014 Report): Profiles of 161 companies

) - Research and Markets ( http://www.researchandmarkets.com/research/k7rqtw/rnai ) has announced the addition of a new report "RNAi - Technologies, Markets and Companies" to their offering.RNA interference (RNAi) or gene silencing involves the use of ... [Published MarketWired - 21 hours ago]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Dicerna Pharmaceuticals : Researchers Demonstrate Promise of Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria Type 1 PH1

By a News Reporter-Staff News Editor at Biotech Week -- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's ... [Published 4 Traders - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

New Small Interference RNAs (siRNAs) Findings Reported from Hokkaido University (Gene silencing via RNAi and siRNA quantification in tumor tissue...

New Small Interference RNAs (siRNAs) Findings Reported from Hokkaido University (Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system)By a News Reporter-Staff News Editor at Biotech Week -- A new ... [Published HispanicBusiness.com - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

ALNYLAM PHARMACEUTICALS : Elects Amy Schulman to its Board of Directors

By a News Reporter-Staff News Editor at Biotech Week -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President ... [Published 4 Traders - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Sirnaomics strengthens IP position for advancing novel siRNA therapeutics programs

Sirnaomics has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled "Multi-Targeted RNAi Therapeutics for Scarless Wound Healing of Skin" (US 8,735,567 B2, PCT/US2008/012498). ... [Published PBR - News - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Is RNAi the Next Big Thing in Weed Management?

If herbicide resistant super weeds aren’t in your area yet, just give it time.Weed control has definitely become more costly in recent years. It seems most are trying to keep fields clean, while holding out for the next big thing.Weed scientists have ... [Published Indiana Prairie Farmer - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Sirnaomics Strengthens Its IP Position for Advancing the Company's Novel siRNA Therapeutics Programs

/PRNewswire/ -- Sirnaomics, Inc. ( www.sirnaomics.com ) announced today that the company has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled " Multi-Targeted RNAi Therapeutics for Scarless Wound ... [Published RCL Advisors - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 2 reports

Alnylam to Host “RNAi Roundtable” Webcast Series

The RNAi Roundtable topics scheduled to date include:Patisiran and ALN-TTRsc for the treatment of Transthyretin-Mediated Amyloidosis (ATTR)Tuesday, July 15: 12:30 – 2:00 p.m. ETJared Gollob, M.D., Vice President, Clinical Research Moderator: John Maraganore, ... [Published Boston Globe - Jul 07 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 2 reports

RXi Pharmaceuticals Appoints Peter Campochiaro M.D. to its Scientific Advisory Board

MARLBOROUGH, Mass.Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGOWith more than 300 articles published in peer-reviewed medical journals, Dr. Campochiaro is a clinician-scientist who does both laboratory and clinical research. His major ... [Published ADVFN UK - Jul 07 2014]

Quotes

"It's ridiculous that we haven't got these [experimental] products out of labs and animal trials and into human testing, and at least offered to people" Farrar told Reuters
...Mark Murray, President and CEO of Tekmira Pharmaceuticals. "We will continue our dialogue with the FDA, provided for under our Fast Track status, in order to advance the development of this important therapeutic agent."
According to The Telegraph she said: "You can't pick up a brain and say "that's a girl's brain, or that's a boy's brain" in the same way you can with the skeleton. They look the same."
...According to news reporting originating from San Francisco, California , by NewsRx correspondents, research stated, "Cancer genomes maintain a complex array of somatic alterations required for maintenance and progression of the disease, posing a challenge to identify driver genes among this genetic disorder. Toward this end, we mapped regions of recurrent amplification in a large collection (n = 392) of primary human cancers and selected 620 genes whose expression is elevated in tumors."

More Content

All (433) | News (258) | Reports (0) | Blogs (145) | Audio/Video (0) | Fact Sheets (3) | Press Releases (25)
sort by: Date | Relevance
Ongoing Ebola outbreak sparks debate on experim... [Published FierceVaccines - 5 hours ago]
The Biotech Bull Market Is Far From Over [Published Chicago Daily Herald - 13 hours ago]
Tekmira Receives Notice of Clinical Hold for TK... [Published Drugs.com - 17 hours ago]
Man, I feel like a woman: Surprisingly simple g... [Published Mail Online UK - 17 hours ago]
14 Insanely Important Biotech/Drug Trading Cata... [Published TheStreet.com - 18 hours ago]
14 Insanely Important Biotech/Drug Trading Cata... [Published The Street Latest - 18 hours ago]
Arrowhead Issues a Statement on Intellectual Pr... [Published Pharma Letter - 20 hours ago]
Global RNAi Technologies, Markets and Companies... [Published MarketWired - 21 hours ago]
Evolution of Sexes Shown by Genetically Enginee... [Published The Guardian Express - Jul 10 2014]
Recent Findings in Cancer Research Described by... [Published 4 Traders - Jul 10 2014]
Tekmira Receives $1.5 Million Milestone Payment [Published GlobeNewswire: Advertising News - Jul 10 2014]
Pixelworks Inc. (PXLW) Leads Small-Cap Stars fo... [Published Equities.com - Jul 09 2014]
New Small Interference RNAs (siRNAs) Findings R... [Published HispanicBusiness.com - Jul 09 2014]
Dicerna Pharmaceuticals : Researchers Demonstra... [Published 4 Traders - Jul 09 2014]
ALNYLAM PHARMACEUTICALS : Elects Amy Schulman t... [Published 4 Traders - Jul 09 2014]
Global Transcriptomics Market : 2014-2018 [Published MarketResearch.com - Jul 09 2014]
Medical News Today: Origin of the sexes: geneti... [Published Medical News Today - Jul 09 2014]
Master regulatory gene for sexes discovered [Published Examiner.com - Jul 09 2014]
Sirnaomics strengthens IP position for advancin... [Published PBR - News - Jul 09 2014]
Is RNAi the Next Big Thing in Weed Management? [Published Indiana Prairie Farmer - Jul 09 2014]
Evolution of Sexes from an Ancestral Mating-Typ... [Published PLoS Biology - Jul 09 2014]
Targeting Nuclear Receptors with Lentivirus-Del... [Published Sexual Development - Jul 09 2014]
Origin of the Sexes: Transgender Algae Reveals ... [Published International Business Times UK - Jul 08 2014]
What Are Little Boys and Girls Made of? The Ori... [Published Plosone.org - Jul 08 2014]
Is This the Crown Jewel of the ISIS Pipeline? [Published Motley Fool - Jul 08 2014]
Tekmira’s TKM-Ebola Phase I trial placed on cli... [Published BioPrepWatch - Jul 08 2014]
Methods and materials for conferring resistance... [Published Free Patents Online - Jul 08 2014]
Sirnaomics Strengthens Its IP Position for Adva... [Published RCL Advisors - Jul 08 2014]
Sirnaomics Strengthens Its IP Position for Adva... [Published PR Newswire: Health - Jul 08 2014]
The pseudo GTPase CENP-M drives human kinetocho... [Published Elifesciences - Jul 08 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Sirnaomics strengthens IP position for advancin... [Published PBR - News - Jul 09 2014]
Sirnaomics has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled "Multi-Targeted RNAi Therapeutics for Scarless Wound Healing of Skin" (US 8,735,567 B2, PCT/US2008/012498). ...
Sirnaomics Strengthens Its IP Position for Adva... [Published PR Newswire: Health - Jul 08 2014]
GAITHERSBURG, Md., July 8, 2014 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled "Multi-Targeted RNAi ...
RNAi Drug Delivery : Technologies and Gobal Mar... [Published PR Newswire: General Business - Jul 07 2014]
NEW YORK, July 7, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:RNAi Drug Delivery : Technologies and Gobal Markets http://www.reportlinker.com/p02212007/RNAi-Drug-Delivery--Technologi ...
Alnylam to Host “RNAi Roundtable” Webcast Series [Published Business Wire Health News - Jul 07 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online “RNAi Roundtables” during July and August. Alnylam scientists and ...
A Modern Solution to Celiac Disease [Published I Am Biotech - Jul 02 2014]
Celiac disease as well as gluten intolerance is widespread amongst the population, but recently a team of talented researchers may have found the solution to their distress- genetically modified wheat. Researchers Cristina Rosella, Francisco Barrob, ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Tekmira Receives $1.5 Million Milestone Payment [Published GlobeNewswire: Advertising News - Jul 10 2014]
Tekmira Receives Notice of Clinical Hold for TK... [Published GlobeNewswire: Acquisitions News - Jul 03 2014]
Tekmira Initiating Phase I/II Clinical Trial in... [Published GlobeNewswire: Acquisitions News - May 27 2014]
Tekmira Provides Corporate Update and Announces... [Published GlobeNewswire: Acquisitions News - May 14 2014]
Tekmira Reports on Voting Results From 2014 Ann... [Published GlobeNewswire: Advertising News - May 09 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.